GPC3-Targeted sdAb-PET Imaging of Hepatocellular Carcinoma with Single-Domain Antibody Tracers

Abstract Glypican-3 (GPC3) is a particular biomarker for hepatocellular carcinoma (HCC). Theranostic strategies targeting GPC3 using single-domain antibodies (sdAbs), also known as nanobodies, show promising potential due to their high affinity and excellent tissue penetration. In this study, two novel GPC3-targeted sdAb-based PET probes were developed and tested in GPC3-positive HCC models. The GPC3-specific sdAb G6 and its albumin-binding domain (ABD)-fused variant ABDG6 were conjugated with NOTA and radiolabeled with [68Ga] to generate [68Ga]Ga-NOTA-G6 and [68Ga]Ga-NOTA-ABDG6, whose binding kinetics, in short-term vitro stability, PET/CT being explore. G6 and ABDG6 showed high affinity for GPC3, with the binding affinity (KD values) of 0.62 nM for G6 and 0.43 nM for ABDG6. After radiolabeling, [68Ga]Ga-NOTA-G6 retained high affinity (KD = 5.4 nM) and demonstrated rapid blood clearance and GPC3-specific tumor accumulation, enabling relatively high-contrast imaging of GPC3 tumors at 60minutes post-injection (p.i.). The uptake of [68Ga]Ga-NOTA-G6 in tumors reached 2.40 ± 0.21 %ID/g, resulting in a high tumor-to-muscle ratio of 3.85 ± 1.32. This uptake could be competitively blocked to a low level (0.74 ± 0.17 %ID/g, P < 0.05). In contrast, [68Ga]Ga-NOTA-ABDG6 showed prolonged circulation and relatively reduced renal uptake. However, its affinity was relatively low (KD = 15.3 nM), and tumor retention did not improve over the 6 h observation period. Taken together, Two GPC3-targeted sdAb PET probes, [68Ga]Ga-NOTA-G6 and [68Ga]Ga-NOTA-ABDG6, were successfully developed. [68Ga]Ga-NOTA-G6 enabled high-contrast, high-specificity imaging of GPC3-positive HCC lesions. Although [68Ga]Ga-NOTA-ABDG6 achieved prolonged circulation, it did not produce enhanced tumor accumulation during the six-hour observation period. Further studies with longer-half-life radionuclides are needed for extended observation.

Authors

Institutions

Publication Details

Journal
Molecular Pharmaceutics
Published
2026-11-16
DOI
https://doi.org/10.1021/acs.molpharmaceut.6c01072
Primary Topic
Radiopharmaceutical Chemistry and Applications
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

GPC3-Targeted sdAb-PET Imaging of Hepatocellular Carcinoma with Single-Domain Antibody Tracers

Yuhang Ye, Weijun Wei, Shimin Ye, Dan Shao et al.
6 links
Molecular Pharmaceutics
Radiopharmaceutical Chemistry and Applications
article

GPC3-Targeted sdAb-PET Imaging of Hepatocellular Carcinoma with Single-Domain Antibody Tracers

Yuhang Ye, Weijun Wei, Shimin Ye, Dan Shao, Dazhi Shi, Jiahao Xie, Yali Yang
article en

Abstract

Abstract Glypican-3 (GPC3) is a particular biomarker for hepatocellular carcinoma (HCC). Theranostic strategies targeting GPC3 using single-domain antibodies (sdAbs), also known as nanobodies, show promising potential due to their high affinity and excellent tissue penetration. In this study, two novel GPC3-targeted sdAb-based PET probes were developed and tested in GPC3-positive HCC models. The GPC3-specific sdAb G6 and its albumin-binding domain (ABD)-fused variant ABDG6 were conjugated with NOTA and radiolabeled with [68Ga] to generate [68Ga]Ga-NOTA-G6 and [68Ga]Ga-NOTA-ABDG6, whose binding kinetics, in short-term vitro stability, PET/CT being explore. G6 and ABDG6 showed high affinity for GPC3, with the binding affinity (KD values) of 0.62 nM for G6 and 0.43 nM for ABDG6. After radiolabeling, [68Ga]Ga-NOTA-G6 retained high affinity (KD = 5.4 nM) and demonstrated rapid blood clearance and GPC3-specific tumor accumulation, enabling relatively high-contrast imaging of GPC3 tumors at 60minutes post-injection (p.i.). The uptake of [68Ga]Ga-NOTA-G6 in tumors reached 2.40 ± 0.21 %ID/g, resulting in a high tumor-to-muscle ratio of 3.85 ± 1.32. This uptake could be competitively blocked to a low level (0.74 ± 0.17 %ID/g, P < 0.05). In contrast, [68Ga]Ga-NOTA-ABDG6 showed prolonged circulation and relatively reduced renal uptake. However, its affinity was relatively low (KD = 15.3 nM), and tumor retention did not improve over the 6 h observation period. Taken together, Two GPC3-targeted sdAb PET probes, [68Ga]Ga-NOTA-G6 and [68Ga]Ga-NOTA-ABDG6, were successfully developed. [68Ga]Ga-NOTA-G6 enabled high-contrast, high-specificity imaging of GPC3-positive HCC lesions. Although [68Ga]Ga-NOTA-ABDG6 achieved prolonged circulation, it did not produce enhanced tumor accumulation during the six-hour observation period. Further studies with longer-half-life radionuclides are needed for extended observation.

Molecular Pharmaceutics
Shanghai Jiao Tong University (CN), Southern Medical University (CN)
National Natural Science Foundation of China
Good health and well-being
Radiopharmaceutical Chemistry and Applications
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon